XTX Topco Ltd Makes New $100,000 Investment in Prelude Therapeutics Incorporated (NASDAQ:PRLD)

XTX Topco Ltd bought a new stake in Prelude Therapeutics Incorporated (NASDAQ:PRLD) in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 48,239 shares of the company’s stock, valued at approximately $100,000. XTX Topco Ltd owned about 0.09% of Prelude Therapeutics as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also recently made changes to their positions in PRLD. Massachusetts Financial Services Co. MA increased its position in Prelude Therapeutics by 2.8% during the second quarter. Massachusetts Financial Services Co. MA now owns 522,375 shares of the company’s stock worth $1,990,000 after buying an additional 14,226 shares during the period. Dimensional Fund Advisors LP increased its holdings in shares of Prelude Therapeutics by 103.2% in the 2nd quarter. Dimensional Fund Advisors LP now owns 29,074 shares of the company’s stock valued at $111,000 after acquiring an additional 14,769 shares during the period. Exchange Traded Concepts LLC raised its position in Prelude Therapeutics by 32.2% in the 3rd quarter. Exchange Traded Concepts LLC now owns 64,409 shares of the company’s stock valued at $133,000 after purchasing an additional 15,682 shares during the last quarter. Walleye Capital LLC boosted its stake in Prelude Therapeutics by 446.2% during the 3rd quarter. Walleye Capital LLC now owns 83,175 shares of the company’s stock worth $172,000 after purchasing an additional 67,946 shares during the period. Finally, State Street Corp boosted its stake in Prelude Therapeutics by 35.1% during the 3rd quarter. State Street Corp now owns 286,046 shares of the company’s stock worth $592,000 after purchasing an additional 74,300 shares during the period. 79.72% of the stock is owned by institutional investors and hedge funds.

Prelude Therapeutics Stock Performance

PRLD stock opened at $1.30 on Friday. The stock has a market capitalization of $71.55 million, a PE ratio of -0.73 and a beta of 1.49. The company has a fifty day moving average of $1.21 and a 200-day moving average of $3.17. Prelude Therapeutics Incorporated has a one year low of $0.80 and a one year high of $6.80.

Prelude Therapeutics (NASDAQ:PRLD) last announced its quarterly earnings data on Wednesday, November 6th. The company reported ($0.43) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.48) by $0.05. The business had revenue of $3.00 million during the quarter. Equities analysts forecast that Prelude Therapeutics Incorporated will post -1.81 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts have commented on the stock. JMP Securities reaffirmed a “market outperform” rating and issued a $4.00 target price (down from $7.00) on shares of Prelude Therapeutics in a report on Wednesday, December 11th. HC Wainwright reaffirmed a “buy” rating and set a $5.00 price objective on shares of Prelude Therapeutics in a research report on Friday, November 8th.

Insider Activity at Prelude Therapeutics

In other Prelude Therapeutics news, CEO Krishna Vaddi acquired 100,000 shares of the business’s stock in a transaction on Wednesday, December 18th. The stock was purchased at an average price of $0.93 per share, for a total transaction of $93,000.00. Following the completion of the transaction, the chief executive officer now owns 1,167,275 shares of the company’s stock, valued at $1,085,565.75. The trade was a 9.37 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 62.80% of the company’s stock.

Prelude Therapeutics Company Profile

Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT1419, a myeloid cell leukemia-1 inhibitor, which is in Phase 1 clinical trial for the treatment of selected relapsed/refractory myeloid or B-cell malignancies; PRT2527, a cyclin-dependent kinase, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; PRT3645, a cyclin-dependent kinase 4/6 inhibitor, which is in Phase 1 clinical trial for the treatment of advanced and metastatic solid tumors; and PRT3879, a SMARCA2 selective protein degrader, which is in Phase 2/3 clinical trial for the treatment of advanced and metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion.